Click here to view online. Add this email to your safelist.
Year-to-date and Q3 2019 Results
24 October 2019
Pascal Soriot, Chief Executive Officer, commenting on the results said:
"With AstraZeneca growing at pace, our sales guidance has been upgraded for the second consecutive quarter. Another strong performance from our new medicines accompanied impressive results in our key markets, most notably in China, the US and Japan. The performance reinforces our confidence in delivering sustainable earnings growth."
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
